arrow
F

Fabian Trillsch

ludwig-maximilians-university munich
H指数:33
被引数:3,550

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer

Durvalumab联合卡铂/紫杉醇和贝伐单抗,然后durvalumab和贝伐单抗联合或不联合奥拉帕尼维持治疗新诊断的非BRCA突变晚期卵巢癌

2025-12-090
PRE
Organoid platinum-resistance model identifies KRT17 as a biomarker of targeted therapy in ovarian cancer

类器官铂耐药模型鉴定KRT17为卵巢癌靶向治疗的生物标志物

2025-11-100
OAAI
Targeted CD47 checkpoint blockade using a mesothelin-directed antibody construct for enhanced solid tumor-specific immunotherapy

靶向CD47检查点阻断,使用一种针对mesothelin的抗体构建体,以增强针对实体瘤的特异性免疫疗法

2025-05-220
OA
Evaluation of therapy support through a standardized nursing consultation for patients undergoing oral tumor therapy in gynecological oncology within the prospective CAMPA initiative

通过前瞻性CAMPA倡议中标准化的护理咨询,对妇科肿瘤学中接受口腔肿瘤治疗的患者的治疗支持进行评估。

2025-02-010
PRE
Palbociclib plus letrozole in estrogen receptor-positive advanced/ recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial

帕博西利联合来曲唑在雌激素受体阳性晚期/复发性子宫内膜癌中的应用:双盲安慰剂对照随机II期ENGOT-EN3/PALEO试验

2025-01-011
OAAI
Anti-angiogenic therapy in first-line treatment of low-grade serous ovarian cancer: Exploratory meta-analysis of the prospective AGO-OVAR 11/12/16 studies

低级别浆液性卵巢癌一线治疗中的抗血管生成疗法:AGO-OVAR 11/12/16前瞻性研究的探索性荟萃分析

2024-09-010
PRE
ASO Visual Abstract: Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome, and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer (HGSOC). A Multicenter, Retrospective Study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium
2022-11-051
PRE
Presence of regulatory T-cells in endometrial cancer predicts poorer overall survival and promotes progression of tumor cells

子宫内膜癌中调节性T细胞的存在预示着较差的总生存期并促进肿瘤细胞的进展

2022-09-137
OAAI
Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium
2022-09-095
OAAI
The Platelet-Activating Factor Receptor's Association with the Outcome of Ovarian Cancer Patients and Its Experimental Inhibition by Rupatadine

血小板活化因子受体与卵巢癌患者预后的关系及其卢帕他定的实验抑制作用

CELLS
IF5.2
2021-09-078
OAAI